XGBoost performed slightly better than logistic regression for predicting recurrence, but it was not competitive with existing published models. Despite this, a future machine learning-based application provided in a bedside setting at low cost might be a clinically useful tool.

To evaluate changes in Clostridioides difficile incidence rates for Maryland hospitals that participated in the Statewide Prevention and Reduction of C. difficile (SPARC) collaborative. Pre-post, difference-in-difference analysis of non-randomised intervention using four quarters of pr …

In murine models of CDI, omadacycline improved survival versus vancomycin. Germinant-antibiotic combinations were more effective at preventing rCDI compared to antibiotics alone without inducing toxin production.

This research provides a straight-forward health systems strengthening intervention for CDI that is both needed and uncomplicated, in an understudied low resource setting. Intervention uptake was highest in the hospital with tension for change, influential champions, and existing academic partnershi …

Pregnant women are at risk for C-diff during and after a hospital delivery. Here are the symptoms to watch out for.

Treatment options for CDI Chair: Giovanni Barbara, Bologna, Italy First-line management, Nicola Petrosillo, Rome, Italy Faecal Microbiota Transplantation (FMT), Gianluca Ianiro (TBC) Followed by Q&A with chairs and speakers

Among adults hospitalized with CDI, peripheral eosinopenia was associated with increased risk of all-cause 30-day mortality. A prediction model incorporating peripheral eosinopenia was developed to improve care for hospitalized patients with CDI through risk stratification.

lth administrative data and validated algorithms, we identified all children (

Vancomycin 🆚 fidaxomicin for Clostridioides difficile infection💊FDX ⬆️ global cure rates💊FDX ⬇️ recurrence rate💊comparable clinical cure rates💊comparable adverse events🥇FDX is superior to VCM in CDI❗️#MedTwitter #GITwitter #IDTwitter #Cdiffhttps://t.co/LRqeiviHg5— John Damianos, M.D. (@john_damianosMD) August 16, 2022

Fidaxomicin (FDX) has received considerable attention as a novel therapeutic alternative agent to vancomycin (VCM) for Clostridioides difficile infect…

FDX achieves significantly higher global cure rates and lower recurrence rates and is comparable to VCM in clinical cure rates and adverse event rates in patients with CDI. Collectively, FDX is superior to VCM as a therapeutic agent for CDI.

Clostridium difficile infection (CDI) is the most common nosocomial infection in hospitals. Despite the fact that CDI has treatment options, recurrence is common after the treatment, recurrence ...

Dr Paul Feuerstadt provides an overview of Clostridioides difficile infection and why it is challenging to manage recurrent C diff infections (rCDI).

To date, no differences have been demonstrated between cefiderocol monotherapy or combination. Further studies are required to understand whether cefiderocol combination therapy could provide an advantage in outcome in seriously-ill patients.

This JAMA Patient Page summarizes the American College of Gastroenterology’s 2021 guidelines on treatment of Clostridioides difficile infection.

Useful algorithm including main steps to consider in a patient with initial or recurrent C. difficile infection 👇https://t.co/ETwfxMUnvc— GutMicrobiota Health (@GMFHx) August 9, 2022

WEBINAR: APIC & SIS Webinar: ID vs Surgeon Symposium | 8/17 | 4 PM ET. Presenters will disuss #Cdiff infection, necrotizing soft tissue infections, diabetic foot infections, and infected vascular catheters, etc. Register now: https://t.co/Hkm0tcFAFm pic.twitter.com/8nDwnmhWwz— APIC (@APIC) August 8, 2022

Treatment of Clostridioides difficile Infection

#Bezlotoxumab in addition to an antibiotic prevents recurrent #Cdiff up to 12 weeks!Useful if one or more of these present:➡️Age 65➡️C.diff in the last 6 months➡️Immunocompromised➡️Severe #CdiffDo not use in heart failure patients pic.twitter.com/kAeiHHFIHn— Sahil Khanna, MBBS, MS, FACG, AGAF (@Khanna_S) July 30, 2022

⚡️QUICK SHOT⚡️What’s your next step in treating recurrent #CDiff in a patient with UC on Stelara failed by vanco taper?💉https://t.co/YoexFSGC4K💉@UmaMahadevanIBD @GIMedEd @colin_feuille #IBD #GITwitter #Meded #FOAMEd @MondayNightIBD @ucsfibd @UCSFGIfellows— IBDLearn (@ibdlearn) August 4, 2022

Top line on @ESCMID guidelines for #Cdiff pic.twitter.com/mPyQUH3Nbc— Sahil Khanna, MBBS, MS, FACG, AGAF (@Khanna_S) July 30, 2022

The current study showed differences in the gut microbiome of UC patients, compared with healthy controls. This may help in identifying the gut microbiome and specific bacterial changes that can be targeted for treatment of UC.

BACKGROUND Splenic abscess is a rare infectious disease that occurs after bloodstream infection and trauma. It has become more common due to an increase in the number of immunocompromised patients. They typically present with round cystic lesions demonstrated by ultrasonography, computed tomography …

In murine models of CDI, omadacycline improved survival versus vancomycin. Germinant-antibiotic combinations were more effective at preventing rCDI compared to antibiotics alone without inducing toxin production.